文献速递支持与姑息治疗

免疫检查点抑制剂相关主要不良心脏事件:美国国家癌症研究所肿瘤治疗评估项目资助试验的汇总分析

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
PubMed 文献 · J Clin Oncol · 2022-06-04

该研究回顾性汇总分析了2015年6月至2019年12月美国国家癌症研究所肿瘤治疗评估项目资助试验的安全性数据库,6925例接受抗PD-(L)1治疗的患者中0.6%(40例)发生ICI相关主要不良心脏事件(MACE),77.5%为≥3级,心肌炎占45%,65%合并其他非心脏irAE;心肌炎相关死亡占22.5%(4/18),4例死亡者均合并肌炎。

要点

  • 6925例接受抗PD-(L)1治疗患者中ICI相关MACE发生率为0.6%(40例),其中77.5%为≥3级。
  • 心肌炎占ICI-MACE的45%(18/40),65%(26/40)合并其他非心脏irAE。
  • 心肌炎相关死亡占22.5%(4/18),4例死亡者均合并肌炎。

核心结论

  • 应强调提高患者和处方者对ICI-MACE模式及合并非心脏irAE的认识。
  • 需要更好地刻画抗PD-(L)1治疗同时联用非ICI类抗癌治疗时MACE的风险特征。

研究设计与样本

  • 采用回顾性汇总分析,数据来源于美国国家癌症研究所肿瘤治疗评估项目的严重不良事件报告数据库,覆盖2015年6月至2019年12月美国国家癌症研究所资助的研究性临床试验。
  • 纳入标准为接受抗程序性细胞死亡蛋白-1(抗PD-1)/程序性细胞死亡配体1(抗PD-L1)单药或联合其他抗癌治疗的患者。
  • 共6925例参与者接受抗PD-(L)1为基础的治疗,其中48%(n=3354)接受抗PD-(L)1单药治疗。

主要发现

  • 6925例患者中0.6%(n=40)符合ICI相关MACE,其中77.5%(31/40)为≥3级。
  • 心肌炎占全部ICI-MACE的45%(18/40)。
  • 65%(26/40)合并其他非心脏irAE的多系统受累;心肌炎患者中83%(15/18)合并一个或多个非心脏irAE。
  • 抗PD-(L)1联合靶向治疗相比抗PD-(L)1联合抗细胞毒性T淋巴细胞相关抗原-4方案,MACE发生率更高(2.1% vs 0.9%,P=.08)。
  • 抗PD-(L)1为基础联合治疗相比抗PD-(L)1单药治疗,心肌炎发生率更高(0.36%,n=13/3571 vs 0.15%,n=5/3354,P=.08)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Major adverse cardiac events (MACEs) because of immune checkpoint inhibitors (ICIs) are infrequent immune-related adverse events (irAEs) that comprise a spectrum of cardiac toxicities with variable manifestations. ICI-related MACEs can lead to significant morbidity and mortality, hence the need to better define presentations of MACEs and their association with noncardiac irAEs in ICI-treated patients. METHODS: We conducted a retrospective pooled analysis of MACE captured in the serious adverse events reporting database of the National Cancer Institute-Cancer Therapy Evaluation Program for National Cancer Institute-sponsored investigational clinical trials between June 2015 and December 2019. Patients were eligible if they had been treated with anti-programmed cell death protein-1 (anti-PD-1)/programmed cell death-ligand 1 (anti-PD-L1) alone or with additional anticancer therapies. RESULTS: A total of 6,925 participants received anti-PD-(L)1-based therapies; 48% (n = 3,354) were treated with single-agent anti-PD-(L)1 therapy. Of 6,925 patients, 0.6% (n = 40) qualified as ICI-related MACE, with 77.5% (n = 31 of 40) being ≥ grade 3. Myocarditis accounted for 45% (n = 18 of 40) of total ICI-MACEs. Concurrent multisystem involvement with other noncardiac irAEs was seen in 65% (n = 26 of 40). Most patients with myocarditis (83%, n = 15 of 18) had one or more noncardiac irAEs associated. Incidence of MACE was higher with anti-PD-(L)1 + targeted therapies compared with anti-PD-(L)1 + anti-cytotoxic T-cell lymphocyte-4 combinations (2.1% v 0.9%, P = .08). There was a higher incidence of myocarditis with anti-PD-(L)1-based combination therapies versus single-agent anti-PD-(L)1 therapies (0.36%, n = 13 of 3,571 v 0.15%, n = 5 of 3,354, P = .08). Deaths related to myocarditis were identified in 22.5% (n = 4 of 18). All four patients who died had concurrent myositis. CONCLUSION: Increasing patient and prescriber awareness in understanding patterns of ICI-MACE and associated noncardiac irAEs should be emphasized. Better characterization of the risk of MACE with the concurrent use of non-ICI-based anticancer therapies with anti-PD-(L)1 treatments is needed.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Naqash AR, Moey MYY, Cherie Tan XW, et al. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program. J Clin Oncol. 2022. PMID: 35658474. doi:10.1200/JCO.22.00369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。